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The concept of distributed manufacturing of chemicals is presented and discussed, with specific focus on the context of 
preparing molecules that can combat the development of geographically-localised resistant strains of infectious 
pathogens. Specifically we present the case of antimalarial compounds and demonstrate that the flow chemistry 
community have already designed both a machine capable of distrubuted chemical manufacturing and a module that 
would be capable of producing artemisin derivatives at the point of use. 
 
 
Introduction 
 
Distributed manufacturing is an emerging technology whereby the 
way in which products are manufactured and distributed is turned 
on its head.1,2 Rather than large scale centralised manufacturing of 
products, distributed manufacturing features a localised smaller 
scale manufacturing at the point-of-use. Distributed manufacturing 
requires the distribution of electronic ‘blue-prints’ to localised 
manufacturing sites and thus offers benefits in the reduction of 
transport and logistics costs, both to the economy and the 
environment. With regards to the distributed manufacturing of 
chemical entities, the on demand preparation of radiolabelled 
tracer compounds represents the only significant development in 
this field.3,4 Such processes use automation to generate the 
radioactive component before reacting this with a precursor 
compound to afford the tracer chemical. The tracer is then purified 
and formulated in an automated fashion prior to use for patient 
diagnostics. Owing to this automated approach one can imagine a 
series of automated modules being distributed into the field for the 
localised and specialised production of chemical entities. Indeed, 
recent results from MIT have described a machine ‘the size of a 
large refrigerator’ that is capable of reconfiguration to produce five 
key drug compounds (Figure 1).5 We envisage such an approach to 
the distributed manufacturing of chemical entities as offering great 
power in situations where the development of resistant strains is an 
issue; such as antibiotics, agrochemicals and neglected tropical 
diseases. Such a manufacturing approach would permit easy 
rotation/interchange of the modules in order to produce different 
small molecule entities in a rotational manner; analogous to crop 
rotation regimes. Such 
 
modules, which are designed with the capability of preparing 
particular chemical entities that are bespoke and specific to 
addressing the localised problem, could then be deployed to the 
localised manufacturing site so as to combat resistance. The 
realisation of such an ideal requires consideration of many hurdles, 
not the least of which is the development of individual modules 
capable of the synthesis, purification and formulation of active 
ingredients. Although, even the latter likely pales into insignificance 
when the hurdle of regulatory control of such a manufacturing 
approach is considered! 
 
The global antimalarial drug discovery portfolio has significantly 
improved over the last 15 years.6–9 In part this is attributable to the 
coordinative work of the Medicines for Malaria Venture (MMV) and 
the Drugs for Neglected Diseases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Compact, modular system used in different configurations to 
synthesise five formulated drugs, developed by MIT. From Science,  
2016, 352, 61-67. Reprinted with permission from AAAS. 
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initiative (DNDi) which were both established in 1999. Amongst 
others, the Bill and Melinda Gates foundation has made significant 
financial contribution to aid this work.10 The portfolio now has the 
opportunity to deliver compounds across a range of modes of 
action, which will be critical to combatting resistance. A distributed 
manufacturing approach where modules are designed for successful 
candidates in this portfolio would enable the rapid rollout of newly 
approved compounds. 
 
Malaria continues to pose a significant threat to a large number 
of people throughout the world, claiming hundreds of thousands of 
lives every year. In 2015 alone, there were over 214 million clinical 
cases reported and an estimated 438 000 deaths, mostly in very 
young children.11 However shocking these figures are, they only 
convey part of the story. The presence of malaria has a detrimental 
effect on a country’s development, with a striking correlation 
between malaria and poverty having been observed.12 Malaria is 
therefore a truly tragic disease, but significant recent progress has 
been made and gives hope that eradication of the parasite will 
eventually be achieved. Of particular note is the recent discovery of 
a CRSIPR-cas9 gene drive system, which targets female 
reproduction in Anopheles gambiae and could suppress mosquito 
numbers to levels that are not conducive to the effective spreading 
of malaria.13 Still, the rollout of such a solution is ethically complex. 
 
 
A major barrier to be overcome in the fight against malaria 
using a chemical approach is resistance. There is now widespread 
resistance to all treatments developed in the last century: 
chloroquine, sulfadoxine–pyrimethamine (SP), 
 
amodiaquine and mefloquine.14 Currently, the artemisinin-based 
combination therapies (ACTs) are used as the first line of 
treatments. However, resistance is developing to this newest  
class of antimalarials, which threatens to reverse recent 
progress.15–18  
Another critical advantageous factor that makes the application of 
distributed manufacturing to addressing tropical diseases an 
interesting proposal is that of drug quality. Often drugs in tropical 
climates can be susceptible to increased rates of degradation, 
criminal production, failed packaging analysis and poor 
manufacturing.19 A localised, distributed manufacturing approach 
would at least minimise the degradation of API materials that result 
from extended and multi-legged transportation routes (which 
include improper climate control) to the point of use. 
 
Herein we provide an overview of the collective automated flow 
synthesis routes to antimalarial compounds. Notably, as a 
community, flow chemists have already collectively designed a 
module for the synthesis of the artemisinin derived antimalarial 
compounds and have demonstrated significant advances towards a 
module for a second endoperoxide; OZ439. 
 
Artemisinin is currently the most effective treatment against the 
malaria parasite. It is used as the first line of treatment, as 
recommended by the WHO, in the form of the artemisinin-based 
combination therapies (ACTs). Global supplies of this vital 
compound are currently extracted from Artemisia annua (Sweet 
wormwood). However, this source causes the supply to be unstable, 
leading to dramatic price fluctuations and increased costs for 
patients.20 
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Scheme 1 Summary of continuous flow approaches to the semisynthesis of artemisinin and its derivatives 
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Scheme 2 Selective reduction of artemisinic acid in flow using the diimide reduction 
 
There is still no commercially viable total synthesis reported, due to 
the complexity of the molecular structure. However, there have 
been several efforts aiming to improve the supply, often employing 
flow processes.  
A common starting point for such efforts is dihydroartemisinic acid 
(DHAA) or artemisinic acid (AA) (Scheme 1). These compounds can 
also be extracted from A. annua in higher yields, but AA can also be 
obtained from glucose using genetically modified yeast.21,22 
Therefore, a semisynthetic strategy from these compounds could 
provide a more reliable global supply of artemisinin. The initial 
singlet oxygen oxidation of DHAA requires the photochemical 
generation of singlet oxygen, and photochemical reactions are 
notoriously challenging to scale up in batch. As such, multiple 
groups have turned to flow methods for the semisynthesis of 
artemisinin from DHAA (Scheme 1). 
 
The first step of this semisynthesis, the selective reduction of 
artemisinic acid (AA) to dihydroartemisinic acid (DHAA), has been 
described by Kappe and co-workers (Scheme 2).23 They report the 
chemo- and diastereoselective reduction of the alkene of the 
vinylogous acid with a high yield using a diimide reduction. This 
process avoids the use of catalysts, allowing for simple reaction 
workup, with side products being water and nitrogen gas. The 
reactive diimide is generated in situ by oxidation of the readily 
available hydrazine hydrate using oxygen. The alkene is then 
reduced by the diimide, liberating nitrogen gas and water (Scheme 
2a). In order to avoid reduction of the internal alkene, the authors 
used a multiple injection strategy. In combination with improved 
mixing due to the segmented flow conditions, this multiple injection 
strategy mimics the slow addition of fresh hydrazine using a 
dropping funnel, driving diimide formation to completion. Using this 
method, DHAA was obtained with 93% isolated yield on an 8.5 
mmol scale with a total reaction time of 37 min. 
 
The next step towards the flow of synthesis of artemisinin is the 
oxidation of DHAA with singlet oxygen in an ene-reaction to yield 
the allylic hydroperoxide (Scheme 1). This intermediate then 
undergoes Hock cleavage which results in ring opening to afford a 
ketone and aldehyde/enol nucleophile. This resulting reactive enol 
then traps triplet oxygen and triggers a triple cyclisation cascade 
that affords artemisinin. 
 
In 2012, Seeberger and Lévesque reported the multistep continuous 
flow synthesis of artemisinin from DHAA.24 Streams of O2 and 
DHAA with a photosensitizer were combined and passed through a 
photo-reactor coil where singlet oxygen is generated (Scheme 3). 
This oxidation is complete after two minutes and after exiting the 
photochemical reactor, a stream of trifluoroacetic acid (TFA) is 
introduced to promote the Hock cleavage. After passing through a 
heated coil for 2.5 minutes, 
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Scheme 3 1st generation synthesis of artemisinin from dihydroartemisinic acid 
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Scheme 4 Synthesis of artemisinin from dihydroartemisinic acid in one reactor moiety remains intact during this reduction process.  
artemisinin was obtained in 39% overall yield from DHAA. This 
setup is capable of producing 200 g of artemisinin per day and scale 
up of the photochemical step is relatively straightforward in flow. 
 
A similar approach towards artemisinin has been developed by 
Rossen, Poliakoff, George and co-workers employing a 
photochemical reactor. In this instance two different strategies 
were explored for all steps from DHAA to artemisinin (Scheme 4).25 
In the first strategy, supercritical carbon dioxide was used as an 
inexpensive, non-toxic solvent, in which singlet oxygen has a 
relatively high lifetime. Streams of DHAA, O2 and CO2 are combined 
and pass into the photo-reactor. The photo-reactor was pre-packed 
with solid supported tetraphenylporphyrin on Amberlyst 15. This 
immobilised catalyst serves two purposes; the porphyrin as a 
photosensitizer for generation of singlet oxygen and Amberlyst 
resin as a Brønsted acid to promote the Hock cleavage. Passing the 
reaction mixture through the reactor 4 times was required to 
achieve full conversion. Subsequent removal of the cosolvent under 
vacuum afforded artemisinin in 51% yield. 
 
 
A second strategy (Scheme 4) used a mixture of solvents 
including water. The photosensitizer was changed to water-soluble 
[Ru(bpy)3]Cl2 and the acid used was now sulfuric acid. These 
materials were introduced in combination with the DHAA and 
combined inline with a stream of O2 before passing into the photo-
reactor, which was packed with glass beads to aid mixing. After a 
residence time of approximately 20 minutes, the output was stirred 
at room temperature for 24 
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Scheme 5 Selective reduction of artemisinin in flow 
 
Seeberger and co-workers further extended their work to 
incorporate multistep processing, whereby the initial 
photochemical process was telescoped into reduction and 
derivatisation steps to deliver artemisinin derived products.31 Key 
to the success was the productive merging of the individual steps. In 
this regard the photosensitizer 9,10-dicyanoanthracene (DCA) was 
combined with a stream of oxygen and passed through the photo-
reactor (Scheme 6). Subsequent passage through a phase separator 
removed any remaining oxygen before proceeding through a 
column packed with sodium borohydride to achieve reduction to 
dihydroartemisinin. This crude material underwent inline liquid-
liquid extraction prior to the final derivatisation reactor sequence. 
The last step consisted of mixing with an appropriate electrophile or 
latent electrophile, passing 
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through a residence coil of 25 minutes, neutralisation and liquid-
liquid extraction to yield three artemisinin derivatives: β-
artemether, β-artemotil and α-artesunate in overall yields of 25, 23 
and 28% respectively. Each stage of the system was monitored for 
quality by inline IR spectroscopy. 
 
This system demonstrates the facile nature by which different 
products can be made using one flow setup. This feature is essential 
for distributed manufacturing systems where new modules can be 
“bolted on” when required in order to synthesise different 
derivatives in different locations. 
 
oxime was then combined with a stream of ozone to synthesise the 
key 1,2,4-trioxolane motif in 70% yield via the Griesbaum co-
ozonolysis. Having achieved a reliable setup for continuous 
synthesis of this intermediate at a rate of 1.9 gh-1, the remaining 
steps were performed in batch. Subsequent deprotection using 
sodium hydroxide generated the phenolate in the presence of 
electrophilic 4-(chloroacetyl)-morphine. After the nucleophilic 
substitution, the amide was reduced using a Zn catalyst in the 
presence of triethoxysilane to afford OZ439 in 86% isolated yield. 
 
As resistance continues to be a problem, it is necessary for new 
compounds to be discovered and manufactured continually. One 
compound showing potent antimalarial properties is OZ-439 
(artefenomel). An important property is that one single, oral dose 
can cause complete eradication of the parasite in humans. It has 
undergone a phase 2a clinical trial, with an estimated parasite 
elimination half-life of 46-62 hours and no serious side effects.32 
However, the original synthesis starts from the relatively costly 4-(4-
hydroxyphenyl) cyclohexan-1-one (USD 10.60/g, Sigma-Aldrich). Ley 
and co-workers have demonstrated the use of flow techniques in a 
synthetic pathway starting from biphenol (USD 3.20/g, Sigma-
Aldrich).33 Initially, the biphenol was reduced by passage through a 
heated column of Pd/C with H2 for 3 minutes to furnish the ketone 
in 58% yield (Scheme 7). The resulting phenol was protected using 
acetic anhydride in a reactor coil held at room temperature with a 
residence time of 40 minutes and quantitative yield. A stream of 
this protected phenol and 
 
Conclusion and Outlook 
 
In conclusion this mini-review/essay has highlighted the potential 
for the distributed manufacturing of chemicals, with specific focus 
on combating the development of geographically-localised resistant 
strains of infectious pathogens. Specifically we present the case of 
antimalarial compounds and summarise the contributions towards 
the continuous synthesis of artemisinin and derivatives as well as 
work towards related endoperoxides. Whilst it is clear that 
regulation and management of both the devices and chemical 
products derived from localised manufacturing would be a key 
critical consideration to help drive this forward, the power of the 
ongoing combination of chemists and chemical engineers working 
together to solve problems relating to human healthcare and 
wellbeing is critical. Indeed, a significant hurdle, which still remains 
to be more frequently considered by the flow chemistry community 
and is critical to the idea of distributed manufacturing of drug 
compounds, 
 
 
dihydroartemisinic   Gas   
acid photo-reactor 
r.t. 
   
0.5 M in Tol     
TFA 0.25 M in Tol    
FlowIR 
 
DCA 0.5 mol%     
(photosensitizer) 
72 W, LED 
    
 6.4 min H2O 
Gas Celite, NaBH4  -20 °C   
O
2 1.1 min    LiCl, Li2CO3 
O + HCl 
    14.5 min 
FlowIR 
    
     
or      
+ HCl      
 
Dilute Acid / Base 
aq waste    
     
   
H β-artemether; R = Me 
or 
   
r.t.   25% yield  
O 
+ Et
3
N  
FlowIR 
 β-artemotil; R = Me 
O   23% yield O 
 
25 min 
 
OR 
α-artesunate; R = OH 
   
  28% yield 
O      
aq waste 
   
     
 
Scheme 6 2nd generation synthesis of artemisinin from dihydroartemisinic acid and subsequent derivatisation using one setup 
 
 
 
 
 
 
 
Please do not adjust margins 
Please do not adjust margins 
 
 
 
 
 H2 
58% 
OH 
 
100 °C 0.25 M  
  5 bar 
0.05 M Pd/C 
DMAP 0.0125 M 
in EtOH/ H2O (1:1) 3 min Et3N 1.12 M 
  in CH2Cl2 
  Ac2O 
  0.3 M 
  in CH2Cl2 
 
 
 
 
 
 
 
 
r.t. 
 
 
40 min 
 6
.9
 b
a
r 
 
OZ439  
New antimalarial candidate 
N 
 
86% (3 steps) 
 
 
 
O3 
 
 
99%  
0.2 M 
 
3 steps in batch 
 
r.t. 
OAc 
 
70% 
1 min 
N 
OMe
 
 
 
0.1 M  
in EtOAc 
 
 
Scheme 7 Cost effective flow synthesis of new antimalarial candidate OZ439 from biphenol in flow 
 
 
 
is the focus on the downstream purification of products, including 
formulation. Such processes have been reported, but not in the 
context of antimalarials and would need to consider solvent 
switching, liquid-liquid extraction, catalyst recovery or recycling, in- 
line analytics, product purification, isolation and formulation. If 
distributed manufacturing is the appropriate solution then such 
considerations would also have to be proven as well as the 
synthetic chemistry. 
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